- Previous Close
0.4026 - Open
0.4029 - Bid 0.4101 x 200
- Ask 0.4187 x 100
- Day's Range
0.4026 - 0.4220 - 52 Week Range
0.1900 - 1.5800 - Volume
413,632 - Avg. Volume
13,090,911 - Market Cap (intraday)
12.218M - Beta (5Y Monthly) 2.13
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.90
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
www.kaziatherapeutics.comRecent News: KZIA
View MorePerformance Overview: KZIA
Trailing total returns as of 7/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KZIA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KZIA
View MoreValuation Measures
Market Cap
11.99M
Enterprise Value
9.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.42%
Return on Equity (ttm)
-186.37%
Revenue (ttm)
560
Net Income Avi to Common (ttm)
-15.7M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
3.56M
Total Debt/Equity (mrq)
6.82%
Levered Free Cash Flow (ttm)
-6.57M